Related Experiment Video
Updated: Mar 2, 2026
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Practical Approach to Triple-Negative Breast Cancer
Vijayakrishna K Gadi1, Nancy E Davidson1
1University of Washington, Fred Hutchinson Cancer Research Center, and Seattle Cancer Care Alliance, Seattle, WA.
Triple-negative breast cancer lacks hormone receptors and HER2. Current systemic treatment relies on chemotherapy, but new targeted therapies, biologics, and immunotherapies show promise for future management.
Area of Science:
- Oncology
- Medical Research
Background:
- Triple-negative breast cancer (TNBC) is defined by the absence of estrogen receptors, progesterone receptors, and HER2 overexpression.
- Current standard systemic treatment for TNBC, in both early and metastatic stages, is cytotoxic chemotherapy.
Purpose of the Study:
- To provide a comprehensive review of evidence-based management strategies for TNBC.
- To discuss emerging treatments including targeted agents, biologics, and immunotherapy for TNBC.
Main Methods:
- Literature review of current and emerging TNBC treatment data.
- Analysis of clinical trial outcomes and research findings.
Main Results:
- Cytotoxic chemotherapy remains the primary systemic treatment for TNBC.
- Significant advancements are being made in targeted therapies, biologics, and immunotherapy for TNBC.
Conclusions:
- While chemotherapy is established, novel therapeutic approaches are poised to transform TNBC treatment.
- Future TNBC management will likely incorporate targeted agents, biologics, and immunotherapy for improved outcomes.
More Related Videos
07:45Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer
Published on: May 18, 2020
13:43Intraductal Delivery and X-ray Visualization of Ethanol-Based Ablative Solution for Prevention and Local Treatment of Breast Cancer in Mouse Models
Published on: April 1, 2022
